The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Biohaven reportedly paid “kickbacks to health care providers to induce prescriptions” of Biohaven’s drug Nurtec ODT. Pfizer, as a result of the action, has agreed to pay $59,746,277 to ...

Pfizer paid $11.6bn to buy Biohaven, largely on the financial performance of Nurtec ODT. The drug went on to generate global sales of $928m in sales in 2023. Known as Vydura in Europe, Nurtec ODT ...

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

NEW YORK (Reuters) - Pfizer will pay $59.7 million to resolve ... kickbacks so doctors would prescribe the migraine drug Nurtec ODT, the U.S. Department of Justice said on Friday.

Nurtec ODT (rimegepant) is a prescription drug that treats and helps prevent migraine episodes. It works by blocking a certain protein in the brain and nervous system that can cause migraine.

After learning doctors weren’t prescrbing its migraine drug Nurtec because they assumed insurance coverage would be a hassle, the company ...

would somewhat slow demand for Pfizer's blockbuster. From its Primary Care segment, I highlight Nurtec ODT/Vydura (rimegepant), a medication for the treatment of various types of migraines ...

Pfizer agreed to pay nearly $60 million to ... at “high end” restaurants in order to persuade them to prescribe Nurtec ODT, the centerpiece of the $11.6 billion acquisition.

Analysts on Wall Street project that Pfizer (PFE) will announce quarterly ... Revenue- Primary Care- Nurtec ODT/Vydura- Worldwide' should come in at $384.55 million. The estimate suggests a ...

Pfizer reported fourth-quarter 2024 adjusted ... Newly acquired product Nurtec ODT/Vydura contributed $392 million in the quarter, which rose 39% year over year, driven by strong demand in the ...